Items-$0.00
Email:sales@ruixibiotech.com
Tel.:02988811435
SP2509 CAS:1423715-09-6
SP2509
| Catalog # | Pkg Size | Price(USD) | Quantity | Buy this product |
|---|---|---|---|---|
| R-C-1125 | 50mg | 225.00 | + Add to cart |
|
| R-C-1125 | 100mg | 425.00 | + Add to cart |
|
| R-C-1125 | 200mg | 615.00 | + Add to cart |
|
|
|
||||
Product description
Soluble in DMSO.LSD1 is a promising target for cancer therapy.Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer.siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells.SP-2528 is a selective and reversible LSD1 inhibitor with an IC(50)of 10nM.SP-2528 demonstrates a high specificity for LSD1,with no effect on MAOi.Target:LSD1.
| Appearance | N/A |
|---|---|
| Molecular Weight | N/A |
| purity | >95% |
| PDI by GPC | <1.5 |
| Solubility | N/A |
| Storage | -20℃, protected from light and moisture |
| Transportation | 4-25℃ temperature for up to 2 weeks |
| Stability | 1 year |
Document
msds----SP2509 Related Product
RuixiBiotechCo.Ltd /KamulinBiotechco.ltd
Add: Room 20F 2002, Meiyuan Building, Yanta District, Xi’ an City, Shaanxi Province 710061 China
Tel: 02988811435
Fax: (86-29)8881-1435
Email: sales@ruixibiotech.com
Web: http://www.ruixibiotech.com
